背景:在撒哈拉以南非洲,皮肤病的疾病负担,包括与皮肤相关的被忽视的热带病(皮肤NTDs),非常高。这些疾病经常被忽视,因为获得医疗保健的机会有限,例如,地理位置偏远,缺乏专家。为了弥补这些差距,我们开发了一个移动健康应用程序,eSkinHealth,这是一个现场适应的平台,可用作便携式电子病历表和远程皮肤病学。
目的:本研究的目的是评估该应用程序在科特迪瓦农村地区诊断和管理皮肤NTDs和其他皮肤病的可用性和有效性。
方法:在3个月的时间内,对当地医疗保健提供者和皮肤病患者进行了一项双臂试验。提供者被分配到接受eSkinHealth应用程序或常规护理控制的干预措施。每组有4名护士和8名社区医护人员参加。仅在干预手臂使用应用程序时提供了培训,而两个手臂都接受过皮肤病方面的训练。对于可用性研究,我们用系统可用性量表(SUS)和深度访谈评估了我们的方法。对于有效性研究,我们的主要结果是评估5种皮肤NTDs作为我们的目标疾病的检测和管理,即,布鲁里溃疡,麻风病,淋巴丝虫病,疮,还有Yaws,使用eSkinHealth应用程序。我们的方法程序已由卫生部机构审查委员会和杜兰大学审查和批准。
结果:我们的参与者(提供者)的平均年龄为40.5岁和42.5岁,分别,全部为男性(n=24)。基线时干预组的平均SUS评分,中点(6周),研究结束(12周)为72.3(SD11.5),72.3(标准差12.4),和86.3(标准差10.8),分别。所有参与者都接受了采访,包括4名皮肤科医生和项目经理,对app感到满意。特别是社区卫生保健工作者感到被配备了该工具所赋予的权力。干预组总共报告了79例皮肤NTDs,而对照组为17例(P=0.002)。除了皮肤的NTD,与干预组相比,对照组报告的皮肤病和状况更多(P<.001).然而,100例(66%)未在对照组中进行任何特殊诊断,仅记录为“皮肤病”。“在干预臂中,在eSkinHealth平台内诊断出151例(72.9%),其余的由皮肤科医生现场诊断。
结论:该研究为我们的监测方法中嵌入的eSkinHealth应用程序的可用性和有效性提供了证据,以改善科特迪瓦和其他皮肤疾病的皮肤NTDs和其他皮肤疾病的检测和管理,此外,预计将有助于了解在资源有限的环境中控制皮肤病的移动健康方法。
背景:ClinicalTrials.govNCT05300399;https://clinicaltrials.gov/ct2/show/NCT05300399。
BACKGROUND: In sub-Saharan Africa, the disease burden from skin diseases, including skin-related neglected tropical diseases (skin NTDs), is extremely high. These diseases often are overlooked due to limited access to health care stemming from, for example, remote geographical locations and a lack of experts. To address these gaps, we developed a mobile health app, eSkinHealth, which is a field-adapted platform to serve as a portable electronic patient chart and for teledermatology.
OBJECTIVE: The purpose of the study is to evaluate the usability and effectiveness of the app in rural Côte d\'Ivoire for diagnosing and managing skin NTDs and other skin diseases.
METHODS: A 2-arm trial with local health care providers and patients with skin diseases was implemented over a 3-month period. The providers were assigned to an intervention receiving the eSkinHealth app or control with usual care. Four nurses and 8 community health care workers participated in each arm. The training was provided on the use of the app to the intervention arm only, while both arms were trained on skin diseases. For the usability study, we evaluated our approach with the System Usability Scale (SUS) and in-depth interviews. For the effectiveness study, our primary outcome was to evaluate the detection and management of 5 skin NTDs as our targeted diseases, namely, Buruli ulcer, leprosy, lymphatic filariasis, scabies, and yaws, using the eSkinHealth app. Procedures of our methods were reviewed and approved by the institutional review board of the Ministry of Health and by Tulane University.
RESULTS: The mean age of our participants (providers) was 40.5 and 42.5 years for the intervention and control arms, respectively, and all were male (n=24). The average SUS scores taken from the intervention arm at baseline, the midpoint (6 weeks), and the end of study (12 weeks) were 72.3 (SD 11.5), 72.3 (SD 12.4), and 86.3 (SD 10.8), respectively. All participants interviewed, including 4 dermatologists and program managers, were satisfied with the app. Especially community health care workers felt empowered by being equipped with the tool. A total of 79 cases of skin NTDs were reported in the intervention arm as compared to 17 cases in the control arm (P=.002). Besides the skin NTDs, more skin diseases and conditions were reported from the control than from the intervention arm (P<.001). However, 100 cases (66%) were not given any particular diagnosis in the control arm and were documented only as a \"dermatosis.\" In the intervention arm, 151 cases (72.9%) were diagnosed within the eSkinHealth platform, and the remaining were diagnosed on-site by dermatologists.
CONCLUSIONS: The study provided evidence for the usability and effectiveness of the eSkinHealth app embedded into our surveillance approach to improve the detection and management of skin NTDs and other skin diseases in Côte d\'Ivoire and, furthermore, is expected to contribute to knowledge on mobile health approaches in the control of skin diseases in resource-limited settings.
BACKGROUND: ClinicalTrials.gov NCT05300399; https://clinicaltrials.gov/ct2/show/NCT05300399.